Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. Julie L. Gerberding, chief patient officer and executive vice president, population health and sustainability, will be retiring from Merck in May 2022.

John Chen, Global Vice President of Abbott and Vice President of Abbott China Core Diagnostics, is leaving Abbott, and Fanny Chen has been appointed as the new Vice President of Core Diagnostics in China.

On February 25, 2022, GUANGZHOU WONDFO BIOTECH CO.,LTD signed a cooperation agreement with Merck, the world's leading technology company.

The COVID-19 pandemic has revealed a frightening reality; the course of infection with this disease is highly variable. Some young patients have died from the virus, whereas some elderly people have survived without experiencing respiratory symptoms at all. Researchers are left wondering: why?

Castle Biosciences reported after the close of the market on Monday that its fourth quarter revenues increased 45 percent year over year, while full-year revenues climbed 50 percent.

Chinese biotech firm SeekIn said on Thursday that it has received CE marking for its SeekInCare Cancer Detection Kit, a DNA-based blood test for early cancer detection.

CareDx reported after close of market on Thursday that its fourth quarter revenues increased 35 percent year over year, driven by testing services.

coronavirus may cause hypogonadism and decreased fertility in male patients, and patients will still be affected after recovery.

Traces of the SARS-CoV-2 coronavirus that causes COVID-19 can be detected in microscopically small fluid droplets exhaled during a very short time span. This is the finding of a new study from the University of Gothenburg.

OraSure Technologies reported after the close of the market Wednesday that its fourth quarter 2021 revenues increased 1 percent year over year.

Agilent Technologies reported after the close of the market on Tuesday that its fiscal first quarter revenues rose 8 percent year over year.

Bio-Techne said on Tuesday that it has inked a development and license agreement with Thermo Fisher Scientific to complete development of and commercialize Bio-Techne's ExoTru kidney transplant rejection test, a multigene urine-based assay.

On February 23, Lepu Biopharma Co., Ltd. was listed on Hong Kong Exchanges and Clearing Limited (HKEX), stock code: 2157.HK. The issue price is HKD 7.13 per share, and public offering raised about HKD 900 million.

Recently, Shenzhen Third People's Hospital/The Second Affiliated Hospital of Southern University of Science and Technology and Roche Diagnostics formally reached a strategic cooperation to jointly establish the "Roche Strategic Cooperation Hospital".

Hypoxia-triggered platinum supernanoparticles dissociated into ultrasmall platinum nanoclusters, which could be cleared by the kidney through urine, in response to the tumor microenvironment.